<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417442</url>
  </required_header>
  <id_info>
    <org_study_id>2011/5</org_study_id>
    <nct_id>NCT01417442</nct_id>
  </id_info>
  <brief_title>BRAF V600E Mutations In Papillary Thyroid Carcinoma</brief_title>
  <official_title>Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bezmialem Vakif University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bezmialem Vakif University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether BRAF V600E mutation in our patients with
      papillary thyroid cancer has an association with poor prognosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF
      V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to
      80%, with the average rate about 45%. Various studies demonstrated a relationship between
      BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient
      prognosis. But,there are no studies from Turkey regarding this topic. So the investigators
      will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this
      mutation in prognosis and further management of the patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BRAF V600E MUTATION</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Papillary Thyroid Carcinoma</condition>
  <arm_group>
    <arm_group_label>BRAF V600E POSITIVITY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>BRAF V600E POSITIVITY</intervention_name>
    <description>BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.</description>
    <arm_group_label>BRAF V600E POSITIVITY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with papillary thyroid cancer

        Exclusion Criteria:

          -  Patients who do not want to be a part of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yeliz Emine Ersoy</name>
      <address>
        <city>Istanbul</city>
        <zip>34308</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeliz E Ersoy, DR</last_name>
      <phone>+905326102713</phone>
      <email>yelizemineersoy@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yeliz E Ersoy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>August 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>August 13, 2011</last_update_submitted>
  <last_update_submitted_qc>August 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yeliz E. Ersoy</name_title>
    <organization>BEZMIALEM VAKIF UNIVERSITY</organization>
  </responsible_party>
  <keyword>papillary thyroid carcinoma</keyword>
  <keyword>BRAF V600E</keyword>
  <keyword>poor prognosis</keyword>
  <keyword>aggressive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

